Ark Biosciences

Ark Biosciences

Dedicated to R&D of innovative therapeutics in the area of viral infection, respiratory, and pediatric diseases

Founded 2014 13 employees Series D Total: $40.09M Biopharma, Biotechnology +2

Ark Biosciences is a biopharmaceutical startup established in 2014 with a clear focus on addressing unfulfilled medical needs related to respiratory viral infections and viral hepatitis. This innovative company aims to cater to both global and Chinese markets, exhibiting a commitment to scientific excellence and innovation in the field of antiviral drug discovery and development. The recent Series D investment on 14 July 2022 brought in substantial support from prominent investors including Qiming Venture Partners, Loyal Valley Capital, Oriental Fortune Capital, Oriza Holdings, Longda Foods, and FTZ Fund. Ark Biosciences operates within the Biopharma, Biotechnology, Health Care, and Pharmaceutical sectors, indicating a diverse and robust market presence. The company's strong emphasis on precision, quickness, and cost-efficiency aligns with contemporary industry demands. Furthermore, its commitment to fostering a supportive and rewarding work environment underscores its dedication to employee well-being. This, in turn, can contribute to the overall success of the organization, ultimately aiming to deliver outstanding returns for its investors and partners.

Funding Stage	Amount	Investors	Lead Investors	Date
Series D	Undisclosed	6	Qiming Venture Partners, Loyal Valley Capital +4	14 Jul 2022
Series C	$86.00K	10	上海浦东科创集团有限公司, Yanchuang Capital +8	22 Jan 2021
Venture Round	Undisclosed	9	Shenzhen Capital Group, Decheng Capital +7	01 Oct 2020
Series B	$32.00M	1	Qiming Venture Partners	01 Jun 2018
Series A	$8.00M	3	Oriza Ventures, Qiming Venture Partners +1	06 Feb 2017
Series A	Undisclosed	3	Qiming Venture Partners, TF Capital +1	01 Mar 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Series D

Undisclosed

Qiming Venture Partners, Loyal Valley Capital +4

14 Jul 2022

Series C

$86.00K

上海浦东科创集团有限公司, Yanchuang Capital +8

22 Jan 2021

Venture Round

Undisclosed

Shenzhen Capital Group, Decheng Capital +7

01 Oct 2020

Series B

$32.00M

Qiming Venture Partners

01 Jun 2018

Series A

$8.00M

Oriza Ventures, Qiming Venture Partners +1

06 Feb 2017

Series A

Undisclosed

Qiming Venture Partners, TF Capital +1

01 Mar 2015

FAQ About Ark Biosciences

Dedicated to R&D of innovative therapeutics in the area of viral infection, respiratory, and pediatric diseases

Ark Biosciences was founded in 2014.

Ark Biosciences operates in Biopharma, Biotechnology, Health Care and Pharmaceutical.

Ark Biosciences has approximately 13 employees.

Ark Biosciences has completed 6 funding rounds, raising a total of $40.09M. The latest funding stage is Series D.

Top alternatives and competitors to Ark Biosciences include Maxwell Biosciences, Blueprint Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Ark Biosciences and Maxwell Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Ark Biosciences

Funding Rounds & Investors (6)

Ark Biosciences Alternatives & Competitors

FAQ About Ark Biosciences